Abbott Laboratories Surprises With Q2 CY2026 Sales Beat
Abbott Laboratories (NYSE:ABT) reported Q2 CY2026 results that surpassed Wall Street expectations, with revenue of $12.59 billion, up 13% year over year. Non-GAAP earnings per share of $1.31 came in 2.6% above analyst consensus.
Key Numbers
Abbott Laboratories (NYSE:ABT) reported Q2 CY2026 financial results that beat Wall Street expectations, with revenue of $12.59 billion, up 13% year over year. Non-GAAP earnings per share of $1.31 exceeded analyst consensus by 2.6%.
Key Financial Results
| Metric | Value | YoY Change |
|---|---|---|
| Revenue | $12.59B | +13% |
| Non-GAAP EPS | $1.31 | +2.6% vs. estimates |
Highlights from the Release
The release did not provide additional details on segment performance or growth drivers. Abbott operates in medical devices, diagnostics, pharmaceuticals, and nutrition.
Guidance
No official guidance was provided for the next quarter or full fiscal year.
Stock Impact
The stock is expected to react positively to the earnings beat, but the magnitude depends on overall market sentiment and sustainability of growth.
What This Means for Investors
The revenue beat and positive earnings surprise indicate strong demand for Abbott's products. Investors should monitor future guidance and segment performance to assess growth sustainability.
Frequently Asked Questions
Found this useful? Share it